Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Wei-Jan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Technology, China Medical University, Taichung, Taiwan; Research Center for Cancer Biology, China Medical Univer…. Hauptthemen laut MEDLINE: SARS-CoV-2, Angiotensin-Converting Enzyme 2, Virus Internalization, Drugs, Chinese Herbal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: China Medical University Hospital, Ministry of Health and Welfare, Tainan Municipal An-Nan Hospital-China Medical University.
Abstract (Originalsprache)
The ongoing COVID-19 pandemic is a persistent challenge, with continued breakthrough infections despite vaccination efforts. This has spurred interest in alternative preventive measures, including dietary and herbal interventions. Previous research has demonstrated that herbal medicines can not only inhibit cancer progression but also combat viral infections, including COVID-19 by targeting SARS-CoV-2, indicating a multifaceted potential to address both viruses and cancer. Here, we found that the Kang Guan Recipe (KGR), a novel herbal medicine formula, associates with potent inhibition activity against the SARS-CoV-2 viral infection. We demonstrate that KGR exhibits inhibitory activity against several SARS-CoV-2 variants of concern (VOCs). Mechanistically, we found that KGR can block the interaction of the viral spike and human angiotensin-converting enzyme 2 (ACE2). Furthermore, we assessed the inhibitory effect of KGR on SARS-CoV-2 viral entry in vivo, observing that serum samples from healthy human subjects having taken KGR exhibited suppressive activity against SARS-CoV-2 variants. Our investigation provides valuable insights into the potential of KGR as a novel herbal-based preventive and therapeutic strategy against COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan; Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.
- Department of Chinese Medicine, China Medical University Hospital, Taichung, 40402, Taiwan.
- Department of Chinese Medicine, China Medical University Hospital, Taichung, 40402, Taiwan; School of Post Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan; Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan.
Förderung
- China Medical University Hospital
- Ministry of Health and Welfare
- Tainan Municipal An-Nan Hospital-China Medical University
- National Science and Technology Council
Zitieren
APA
Wang, W. J., Tang, H. T., Ou, S. C., Shen, W. J., Chen, C. Y., Li, Y. C., Chang, S. Y., Chang, W. C., Hsueh, P. R., Huang, S. T., & Hung, M. C. (2024). Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217198
Vancouver
Wang WJ, Tang HT, Ou SC, Shen WJ, Chen CY, Li YC, et al. Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217198
BibTeX
@article{Wang2024,
author = {Wang, Wei-Jan and Tang, Hsuan-Ting and Ou, Shi-Chen and Shen, Wan-Jou and Chen, Chung-Yu and Li, Yi-Chuan and Chang, Sui-Yuan and Chang, Wei-Chao and Hsueh, Po-Ren and Huang, Sheng-Teng and Hung, Mien-Chie},
title = {Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217198}
}
EUVIMED